CIN 210
Alternative Names: CIN-210Latest Information Update: 04 Jun 2024
At a glance
- Originator Janssen Sciences Ireland UC
- Developer CinFina Pharma
- Class Obesity therapies
- Mechanism of Action Glucagon-like peptide stimulants; Neuropeptide Y receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity